Christopher J. Kane, MD, FACS, Chair, Department of Urology and Professor of Surgery, is the Cancer and Leukemia Group B (CALGB) principal investigator for the Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma (ASSURE) study. In addition to many projects within Urology and the Department of Surgery, he also collaborates with: Dr. Michael Karin on the role of B-cells in the development of potential therapies for patients with castrate-resistant prostate cancer; Dr. Roger Tsien on the imaging of neural peptides for surgical molecular guidance during prostatectomy; and with Dr. David Vera on lymphatic imaging and urologic malignancies.
C. Lowell Parsons, MD, FACS, Professor Emeritus, is one of the world's leading researchers in the causes, diagnosis, and treatment of interstitial cystitis (IC). His research team has identified a defect in Tamm-Horsfall protein (a urinary protein) that is present in patients with IC.
Michael Albo, MD, FACS, Professor of Surgery and Vice Chair of Urology, is co-principal investigator of the largest clinical site in the multicenter Urinary Incontinence Treatment Network (UITN). The UITN involves clinical research centers throughout the United States in a cooperative, ongoing effort to evaluate the effectiveness of medical and surgical treatments for urinary incontinence. Dr. Albo is also Co-Director and founder of the UCSD Healthcare Women’s Pelvic Medicine Center.
Roger Sur, MD, Associate Professor of Surgery, is the Director of the UCSD Comprehensive Kidney Stone Center. He is investigating the role of Tamm-Horsfall protein in kidney stone formation and the role of weight reduction in preventing kidney stones.
J. Kellogg Parsons, MD, MHS, FACS, Associate Professor of Surgery, pursues clinical trials and collaborative studies in the epidemiology of prostate cancer, the epidemiology of BPH, surgical outcomes, patient safety, and evidence-based medicine. He is collaborating with Frederick Millard, MD, Professor of Medicine at Moores Cancer Center in a clinical trial of sipuleucel-T (Provenge), an immunotherapy for androgen-independent prostate cancer.
Ithaar Derweesh, MD, Professor of Surgery, specializes in laparoscopic surgery and kidney-preserving treatment for kidney cancer. He is senior author of a study that demonstrates the safety and efficacy of sunitinib for shrinking advanced kidney cancers prior to partial kidney removal and reconstruction.
Christina Jamieson, PhD, Associate Professor, is working to identify genes that are specifically associated with cancer proliferation in bone to develop targeted drug therapies for patients with androgen-independent prostate cancer that is resistant to other treatments. Translating these findings into novel therapeutic applications will improve and eventually transform patient care.
George Chiang, MD, Associate Professor, is reviewing incidental urological findings in more than 3,000 CT scans performed in the emergency department. This study would serve as a basis for determining the prevalence of various urological conditions in children.
A. Karim Kader, MD, Associate Professor of Surgery, has two patents pending, one on multiple genetic polymorphisms (SNPs) that can be used to predict prostate cancer risk, and the other on a prostate cancer brachytherapy delivery device. He is a co-investigator on a multidisciplinary NIH grant to study the clinical validity and utility of genomic targeted chemoprevention of prostate cancer.